Fellowship in Stem Cell Transplant & Cellular Therapy

One year Stem Cell Transplant/Cellular Therapy Fellowship at the Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai (Non-AGCME accredited).

Immersive experience to jumpstart an academic career in allogeneic/autologous transplantation and stem cell therapy. The program includes training in the inpatient and outpatient settings to develop all competencies required by FACT for transplant physicians.

Rotations in the HLA and cell processing laboratories are aimed to gain in-depth knowledge of donor identification, selection of stem cell source, use of donor registries and cell processing. The fellow will participate in bone marrow harvesting procedures and stem cell collections by apheresis. Active participation in M&M, QA/QI, Tumor Board and Grand Rounds is expected.

Development of a research plan with strong mentorship is a requirement of the fellowship. Examples of mentored research programs that BMT Fellows may explore include:

- Clinical research programs in transplantation for MDS, MPN, leukemia, lymphoma and plasma cell disorders, immune effector cell therapies
- Translational research in dendritic cell vaccines, myeloid suppressor cells, GVHD, stem cell mobilization and homing
- Basic research programs in stem cell biology and immunology of transplantation
- Outcomes and psychosocial aspects of transplantation
- Disparities in transplant research

About Mount Sinai:
The Icahn School of Medicine at Mount Sinai BMT Program is accredited by FACT and performs nearly 300 transplants per year including autologous, allogeneic [related, unrelated, haplo-identical and cord]). The Program is part of the Division of Hematology/Oncology and the Tisch Cancer Institute and is recognized by NMDP as a transplantation and bone marrow and stem cell collection center and as a transplantation research site for CALGB and COG.

- Large number of faculty members focused on stem cell transplantation, lymphoid and myeloid malignancies, MPN and MDS with an extensive, peer-review funded research portfolio.
- Robust program in immune effector cell therapy offering multiple open clinical trials (multiple myeloma, lymphoma, ALL) as well as commercial CAR T-cell therapies for eligible patients.
- Mount Sinai leads one of the only multicenter GVHD clinical research trial networks in the United States.

How to Apply:
Applications for a fellowship start date July 1, 2022 and July 1, 2023 are currently being accepted. Applicants must be board-eligible/board-certified graduates of accredited US Hematology/Oncology fellowship programs or equivalent.

For further information please contact:
Ms. Wanda Johnson wanda.johnson@mssm.edu (212) 241-4705
Adriana K. Malone, MD, Program Director adriana.malone@mountsinai.org (212) 241-6021